It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016

News Releases2016

September
Pharmaceuticals
Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
Pharmaceuticals
Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder
Pharmaceuticals
ICLUSIG® Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
U.S. FDA Approves Labeling Update of REXULTI®(brexpiprazole) for Maintenance Treatment of Schizophrenia in Patients in the U.S.
Pharmaceuticals
Headline conclusions from the phase III study of idalopirdine (Lu AE58054) for cognitive symptoms associated with Alzheimer's disease
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Yamanashi Prefecture
Pharmaceuticals
Announcement of Co-promotion of New Glaucoma Treatment (PDF:45.7 KB)
Pharmaceuticals
Otsuka and NEC agree to develop a smart medicine container to assist patients in taking daily anti-stroke medication at the appropriate time
Nutraceuticals
Otsuka Pharmaceutical Enters into Partnership Agreement with Yamagata Prefecture, Aiming to Achieve Japan's Top Healthy Life Expectancy
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Kanagawa Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Health Promotion Partnership with Kumamoto Prefecture
Pharmaceuticals
RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launches (PDF:90.0 KB)